Browse RMM Directory A-Z

Dabigatran Krka Prescriber Guide for primary prevention of venous thromboembolic events (VTE) following elective total hip or knee replacement surgery

${pdf_link}$

Dabigatran Prescriber Guide - paediatric use

Prescriber guide for paediatric use

${pdf_link}$

Dabigatran Prescriber Guide for prevention of VTE

Prescriber Guide for prevention of VTE

${pdf_link}$

Dabigatran Prescriber Guide for stroke prevention

Prescriber Guide for stroke prevention

${pdf_link}$

Dabigatran Etexilate Paediatric - Guide

This guide provides recommendations for the use of dabigatran etexilate in the paediatric population in order to minimise the risk of bleeding

${pdf_link}$

Dabigatran Etexilate Stroke - Guide

This guide provides recommendations for the use of dabigatran in order to minimise the risk of bleeding

${pdf_link}$

Dabigatran Etexilate Hip, Knee - Guide

This guide provides recommendations for the use of dabigatran in order to minimise the risk of bleeding

${pdf_link}$

Dabigatran Etexilate- Patient Alert Card

Dabigatran etexilate Information for Patients / Caregivers of paediatric patients

${pdf_link}$

Patient Alert Card

Information about the potential risk of bleeding during treatment with dabigatran etexilate and guidance on how to manage that risk.

${pdf_link}$

Prescriber Guide for paediatric use

Indication
Contraindications
Dosing Special patient populations potentially at high risk of bleeding
Perioperative management
Coagulation tests and their interpretation
Overdose
Management of bleeding complications
Patient Alert Card and counselling

${pdf_link}$

Prescriber Guide for stroke prevention in atrial fibrillation and treatment and prevention of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults

Indications
Contraindications
Perioperative management
Dosing
Special patient populations potentially at higher risk of bleeding
Coagulation tests and their interpretation
Overdose
Management of bleeding complications
Patient Alert Card and counselling

${pdf_link}$

Prescriber Guide for venous thromboembolic events (VTE) following elective total hip or knee replacement surgery

Indication
Contraindications
Dosing
Special patient populations potentially at high risk of bleeding
Coagulation tests and their interpretation
Overdose
Management of bleeding complications
Dabigatran etexilate Patient Alert Card and counselling

${pdf_link}$

Dabigatran etexilate- Patient Alert Card

Patient Alert card

${pdf_link}$

Dabigatran etexilate-Prescriber Guide (deep vein thrombosis & pulmonary embolism)

${pdf_link}$

Dabigatran etexilate-Prescriber Guide (paediatric use)

${pdf_link}$

Dabigatran etexilate-Prescriber Guide (prevention of venous thromboembolic events)

${pdf_link}$

HCPs-_Important information on safety and risk minimisation of Daratumumab and interference with Blood Compatability Testing

Inform health care professionals of the interference of Darzalex (daratumumab) with antibody screening and crossmatching

${pdf_link}$

Important Information about Blood Transfusions

Card for patient's receiving Darzalex (daratumumab)- patient should carry this card while receiving treatment and for 6 months after treatment has ended.

${pdf_link}$

Important information on safety and risk minimisation of Daratumumab and Interference with Blood Compatibility Testing

Information for Blood Banks on the intereference with Antiglobulin Test _blood typing

${pdf_link}$

Daurismo (glasdegib) Patient Alert Card

Patient alert card for male patients regarding the risk of embryo-foetal risks of exposure to women of child-bearing potential by semen associated with DAURISMO

${pdf_link}$

Important Information for Healthcare Professionals

${pdf_link}$

Important information for patients

${pdf_link}$

Physician’s reference checklist for Deferasirox

${pdf_link}$

Deferasirox Important information for patients about your treatment and possible side effects

Please keep this document safe for future reference. This booklet is only intended for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.

${pdf_link}$

Deferasirox Physicians Reference Checklist.

Checklist for dosing and biological monitoring

${pdf_link}$

Important Information to Remember About deferasirox Treatment.

This booklet provides detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment.

${pdf_link}$

Important information for Healthcare Professionals

minimise key adverse effects including medication errors during treatment

${pdf_link}$

Important information for patients about your treatment and possible side effects

Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring your treatment is important, and which medicines you can take while on deferasirox.

${pdf_link}$

Physician’s reference checklist for Deferasirox (deferasirox) dosing and biological monitoring

Document highlights important information about requirements for Deferasirox (deferasirox) dosing, dose adjustment and biological monitoring.

${pdf_link}$

Important information for Healthcare Professionals

Booklet with detailed information on posology and monitoring of patients on deferasirox, to minimise key adverse effects including medication errors during treatment

${pdf_link}$

Important information for Patients

Booklet for patients that have been prescribed deferasirox. It contains important information, including how to take deferasirox the right way, why monitoring of your treatment is important, and which medicines you can take while on deferasirox.

${pdf_link}$

Physician´s reference checklist

Checklist for deferasirox dosing, dose adjustment and biological monitoring.

${pdf_link}$

Deferasirox Important information for patients about your treatment and possible side effects

${pdf_link}$

Important Information to Remember About Deferasirox Treatment

${pdf_link}$

Physician’s reference checklist for Deferasirox

${pdf_link}$

Communication plan-Deferasirox

Communication plan for deferasirox tablets

${pdf_link}$

Information for HCPs-Deferasirox

Important Information for Healthcare Professionals to Remember About Deferasirox SUN (deferasirox) Treatment

${pdf_link}$

Information for patients-Deferasirox

Important information for patients about your treatment and possible side effects - Deferasirox

${pdf_link}$

Physician reference checklist - Deferasirox

Physician’s reference checklist for Deferasiroxdosing and biological monitoring

${pdf_link}$

Deferasirox HCP Information Brochure

${pdf_link}$

Deferasirox Patient Information Brochure

${pdf_link}$

Deferasirox Physician's Reference Checklist

${pdf_link}$

Deferasirox HCP Information Brochure

${pdf_link}$

Deferasirox Patient Information Brochure

${pdf_link}$

Deferasirox Physician's Reference Checklist

Physicians reference checklist for dosing and monitoring

${pdf_link}$

Patient/Carer Reminder Card

Important Safety Reminders for Patients taking Deferiprone tablets

${pdf_link}$

Valproate- “White Box” Warning Labels

FOR DISPENSARY USE ONLY Warning Labels with Valproate Pregnancy Pictogram for Pharmacy to use with white box dispensing of these products. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate Female Annual Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for use with girls and women of childbearing potential taking this product. It is to be completed with their specialist at least once a year to make sure they know and have understood all the risks related to the use of valproate during pregnancy and the need to avoid becoming pregnant while taking valproate.

${pdf_link}$

Valproate- Healthcare professionals (HCPs) Guide

Educational material for Healthcare Professionals on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate Male Risk Acknowledgement Form

THIS INTERACTIVE FORM IS NOT INTENDED FOR HARD COPY USE Interactive form for male patients aged under 55 years to complete with their specialists when starting valproate

${pdf_link}$

Valproate- Patient Card-Contraception and Pregnancy Prevention

Educational material for girls and women of childbearing potential about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate- Patient Guide

Educational material for patients on important safety information associated with Valproate use. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

Valproate- Poster- Dispensary- Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

${pdf_link}$

DOSING CARD: Dexamethasone 3.8 mg/ml solution for injection

Dosing Card

${pdf_link}$

Boys 2-18 years growth chart

This chart is mainly intended to assess the growth of school age boys. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.

${pdf_link}$

Chart for ongoing monitoring during Dexamfetamine sulfate treatment

A form template according to prescribing information in more detail, growth, psychiatric and cardiovascular status should be regularly monitored.

${pdf_link}$

Dexamfetamine checklist 1

Checklist 1: checklist before prescribing Dexamfetamine sulfate 5 mg tablets

${pdf_link}$

Dexamfetamine checklist 2

Checklist 2: checklist for monitoring of ongoing therapy with Dexamfetamine sulfate 5 mg tablets.

${pdf_link}$

Dexamfetamine consideration

Consideration when ending treatment with Dexamfetamine sulfate 5mg Tablets

${pdf_link}$

Dexamfetamine Pharmacist Information

This sheet provides additional information on Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate).

${pdf_link}$

Dexamfetamine Physician Information

A physician’s guide to prescribing Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)

${pdf_link}$

Girls UK Growth chart 2-18 years

This chart is mainly intended to assess the growth of school age girls. It combines data from the UK 1990 growth reference for children at birth and from 4 -18 years, with the WHO growth standard for children aged 2 years to 4 years. The growth of children under 2 years of age should be plotted on the more detailed UK-WHO 0-4 years growth charts.

${pdf_link}$

Information for parents and carers

Information for parents and carers of patients prescribed with Dexamfetamine sulfate 5 mg tablets (dexamfetamine sulfate)

${pdf_link}$

Dexamfetamine Sulfate 5mg tablets

Educational materials for Dexamfetamine Sulfate 5mg tablets-PL 06464/3115 These materials have been designed to support you in the appropriate prescription and administration of Dexamfetamine Sulfate 5 mg tablets for the treatment of patients with ADHD. It is recommended that these materials be used in conjunction with the full prescribing information for the product.

${pdf_link}$

HCP Educational Material Ferric Derisomaltose

IV iron. Essential Prescription and Administration Information to Minimise the Risk of Serious Hypersensitivity Reactions

${pdf_link}$

Patient Educational Material Ferric derisomaltose

Intravenous (IV) Iron. Important Information for Patients about the Possible Risk of Serious Allergic Reactions with IV iron treatment (iron given by injection or infusion into a vein)

${pdf_link}$

Dianette Patient Card UK

Dianette patient information card.

${pdf_link}$

Dianette Prescriber Checklist UK

Dianette - checklist for prescribers.

${pdf_link}$

Dronedarone Aristo Prescribers Guide

Safety information for the use of Dronedarone Aristo

${pdf_link}$

Dronedarone 400 mg film-coated tablets

DRONEDARONE PRESCRIBER GUIDE

${pdf_link}$

Patient Card

Information card for women about the risk of blood clots.

${pdf_link}$

Prescriber Checklist

Prescriber checklist to be used in conjunction with the Summary of Product Characteristics during combined hormonal contraceptive (CHC) consultations.

${pdf_link}$

Duodopa HCP Guide

This guide is an educational material as part of the additional risk minimisation program

for Duodopa. This guide is intended to inform gastroenterologists, neurologists and other

healthcare professionals (HCPs) with recommended measures to minimise gastrointestinal,

gastrointestinal device, and gastrointestinal procedure related events.

${pdf_link}$

Duodopa Patient guide

This guide is for patients and caregivers of patients who are using Duodopa as a

treatment for advanced Parkinson’s disease (PD).

${pdf_link}$

Dymista Control Pharmacy Essential Guide

Pharmacy Essential Guide for Dymista Control

${pdf_link}$

Valproate - Annual Risk Acknowledgement Form for females GB & NI 2023 - aRMM

Further to the National Patient Safety Alert issued on 28 November 2023, the purpose of this letter is to notify you of an important restriction of indication for new male patients and all female patients aged under 55 years, along with updated contraindications, warnings, and measures to prevent valproate exposure during pregnancy, as well as the availability of revised educational materials to support discussions with patients.

${pdf_link}$

Valproate - Poster-Dispensary-Pregnancy Prevention Programme

FOR DISPENSARY USE ONLY Dispensary A4 Poster for Pharmacy with key information about the Pregnancy Prevention Programme.

${pdf_link}$

Valproate - Risk Acknowledgement Form for males GB & NI 2023 - aRMM

Further to the National Patient Safety Alert issued on 28 November 2023, the purpose of this letter is to notify you of an important restriction of indication for new male patients and all female patients aged under 55 years, along with updated contraindications, warnings, and measures to prevent valproate exposure during pregnancy, as well as the availability of revised educational materials to support discussions with patients.

${pdf_link}$

Risk Minimisation Materials

Dabigatran

Biocon Pharma UK Limited

Genus Pharmaceuticals

Krka UK Ltd

Zentiva

Dabigatran etexilate

Glenmark Pharmaceuticals Europe Ltd

Laboratorios Liconsa, S.A.

Sandoz Limited

Darzalex

Janssen-Cilag Ltd (a Johnson & Johnson Company)

Daurismo

Pfizer Limited

Deferasirox

Amarox Limited

Dr. Reddy's Laboratories (UK) Ltd

Glenmark Pharmaceuticals Europe Ltd

MSN Laboratories Europe Ltd

Mylan

Ranbaxy (UK) Limited a Sun Pharmaceutical Company

Teva UK Limited

Zentiva

deferiprone

ADVANZ Pharma

Depakote

SANOFI

Dexamethasone

Aspen

Dexamfetamine

Brown & Burk UK Ltd

Sovereign Medical

Diafer

Pharmacosmos UK Limited

Dianette

Bayer plc

Dronedarone

Aristo Pharma Limited

Aurobindo Pharma - Milpharm Ltd.

Drovelis

Gedeon Richter (UK) Ltd

Duodopa

AbbVie Ltd

Dymista Control

Mylan

Dyzantil

Aspire Pharma Ltd

You are trying to reach document intended for healthcare professionals only.